OPG, a promising biomarker for atherosclerosis, can significantly improve cardiovascular risk prediction; however, the lack of standardized assays to measure OPG levels and variability in reference ranges can hinder its consistent clinical use. The gene discussed is TNFRSF11B; the disease is atherosclerosis.